TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04770272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy Arm A
Description: 1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy Arm B
Description: 1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
Study: NCT04819425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Adhesive Strips
Description: Securement of Endotracheal tube with Elastic Adhesive Strips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lace in A Protective Sheath
Description: Securement of Endotracheal tube with Lace in A Protective Sheath
Study: NCT05045755

Intervention type: BIOLOGICAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
Study: NCT05174572

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IMR
Description: Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
Study: NCT03698162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo STAR DCE-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo STAR DCE-MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
Study: NCT04853303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypnosis VR
Description: Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
Study: NCT05120843

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care coordination and motivational interviewing
Description: Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
Study: NCT05852600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Adolescents Talking about Healthy Sexuality (PATHS)
Description: PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
Study: NCT05294471

Intervention type: DEVICE
Intervention: Non-contrast MRI with novel MRI software
Description: The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.

Intervention type: DEVICE
Intervention: Non-contrast MRI with novel MRI software
Description: The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.

Intervention type: DEVICE
Intervention: Non-contrast MRI with novel MRI software
Description: The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.

Intervention type: DEVICE
Intervention: Non-contrast MRI with novel MRI software
Description: The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
Study: NCT06551090

Intervention type: OTHER
Intervention: CAMERA (Context-Aware Multimodal Ecological Research and Assessment)
Description: The CAMERA platform is a multimodal, hardware-software framework for measuring brain-behavior interactions in an unstructured environment and predict ecological states. CAMERA will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy. CAMERA consists of: Wristband sensors of autonomic physiologic signals, emphasizing heart rate metrics and electrodermal activity; Smartphone usage, emphasizing natural language processing of text input for linguistic features; Subject-tracking audiovisual array, emphasizing subject vocal activity; Intracranial neural recordings, emphasizing hippocampal theta power and high-frequency activity (\~70-200 Hz).
Study: NCT06249672

Intervention type: OTHER
Intervention: Local excision
Description: Organ preservation after RCT (radiochemotherapy) of rectal cancer
Study: NCT06584409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Pen
Description: Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
Study: NCT05003895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: Single infusion on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: Single infusion on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
Study: NCT04493645

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation (SOC)
Description: 6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot Intensive Rehabilitation (FIRE)
Description: 6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
Study: NCT06485609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
Description: radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
Study: NCT05743595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized Neoantigen DNA vaccine
Description: The sites of immunization may be rotated for each of the immunizations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized Neoantigen DNA vaccine
Description: The sites of immunization may be rotated for each of the immunizations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be supplied by Incyte.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be supplied by Incyte.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM v 2.0 electroporation device
Description: Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM v 2.0 electroporation device
Description: Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
Study: NCT06276686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Vigorous intensity aerobic interval exercise
Description: 11-weeks course of aerobic and resistance exercise, delivered 2 weeks before long course NACRT, 5-weeks during NACRT and 4 weeks post NACRT. Alongside twice weekly unsupervised resistance exercise training.
Study: NCT04518280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Shor-course radiotherapy: 25Gy/5Fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Shor-course radiotherapy: 25Gy/5Fx
Study: NCT05427812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 1442 SC injection escalating doses
Description: Participants will receive escalating SC doses of ISB 1442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 1442 SC injection at RP2D
Description: ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
Study: NCT06269978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and IP fluid samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Laparoscopy
Description: Undergo diagnostic laparoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given via IP infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given via IP infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo placement of indwelling IP port
Study: NCT06185023

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity physical exercise
Description: As an active control intervention, a low-intensity non-aerobic exercise program was selected that mirrors more closely the standard-of-care physical therapy currently provided to stroke patients. This control intervention will offer the same level of participant involvement and type of exercises, but without the intensity element, i.e., it will not incorporate the cardiovascular and the strengthening components.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity physical exercise
Description: We have developed a new exercise program specifically designed for individuals with post-stroke aphasia, Aphasia Physical EXercise (APEX), to provide a safe, stroke- and aphasia-friendly physical exercise intervention to achieve optimal physical fitness and cognitive/language gains. This intervention, based on published research and clinical practice recommendations, is a high-intensity interval training full-body workout optimized to accommodate the range of motor abilities and general deconditioning observed in stroke survivors.
Study: NCT05822297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
Study: NCT06097260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06232109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: Oral
Study: NCT06470659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Clinic
Description: Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW
Study: NCT05554848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
Study: NCT05837975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FREE Walk Exoskeleton
Description: Using a robotic exoskeleton to help with lower limb activities that are difficult due to neurological diseases. Used at home for individual patient training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FREE Walk Exoskeleton
Description: Using a robotic exoskeleton to help with lower limb activities that are difficult due to neurological diseases. Used at home for individual patient training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Rehabilitation
Description: Traditional rehabilitation refers to the use of conventional therapeutic methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Rehabilitation
Description: Traditional rehabilitation refers to the use of conventional therapeutic methods.
Study: NCT05994937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAC with HEPA filter intact
Description: A commercially available PAC with a true HEPA filter will be used. Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PAC with HEPA filter removed
Description: Uses the same model as the experimental PAC that is identical in appearance and sound with the HEPA filter removed . Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
Study: NCT05854836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)
Description: CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
Study: NCT05624060

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Dysfunction Prevention Training
Description: The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Dysfunction Prevention Training
Description: The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Dysfunction Prevention Training
Description: The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Dysfunction Prevention Training and Perineal Massage
Description: Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Dysfunction Prevention Training and Perineal Massage
Description: Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise
Description: Women assigned to this group will apply pelvic floor exercise at least 3 days a week 8-12 times a week, starting from the 34th week of pregnancy until delivery. In addition, women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant.
Study: NCT06386185

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheter
Description: Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
Study: NCT05238376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
Study: NCT06351267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability Exercises
Description: Core stability exercises will be used to strengthen the core muscles, which includes sets of exercises like pelvic tilts, wall squatting, bridging, bird dog and heel walking which targets core muscles.